Beth Overmoyer

Mar 19, 2024 | nature.com | Ann H. Partridge |Beth Overmoyer |Nabihah Tayob |Sara M. Tolaney |Qingchun Jin |Alyssa Pereslete | +1 more

AbstractThe landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. Here we present the final results of a phase Ib/IIa, open-label trial (NCT02871791) of exemestane plus everolimus and palbociclib for CDK4/6i-resistant metastatic breast cancer.

Jun 2, 2023 | nature.com | Priscilla K Brastianos |Anita Giobbie-Hurder |Beth Overmoyer |Sara M. Tolaney |Erica L. Mayer

AbstractBrain metastases (BMs) are an emerging challenge in oncology due to increasing incidence and limited treatments. Here, we present results of a single-arm, open-label, phase 2 trial evaluating intracranial efficacy of pembrolizumab, a programmed cell death protein 1 inhibitor, in 9 patients with untreated BMs (cohort A) and 48 patients with recurrent and progressive BMs (cohort B) across different histologies.

Jun 2, 2023 | nature.com | Ana C. Garrido-Castro |Faina Nakhlis |Laura Warren |Beth Harrison |Sara M. Tolaney |Beth Overmoyer

AbstractInflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer that presents as de novo metastatic disease in 20–30% of cases, with one-third of cases demonstrating HER2-positivity. There has been limited investigation into locoregional therapy utilization following HER2-directed systemic therapy for these patients, and their locoregional progression or recurrence (LRPR) and survival outcomes.